486
Participants
Start Date
January 25, 2019
Primary Completion Date
May 21, 2022
Study Completion Date
May 21, 2022
Dupilumab SAR231893
"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
Placebo
"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
Asthma Controller Therapies (include prednisone/prednisolone)
"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
Asthma Reliever Therapies
"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
Investigational Site Number :1560016, Beijing
Investigational Site Number :1560029, Beijing
Investigational Site Number :1560015, Beijing
Investigational Site Number :1560018, Shenyang
Investigational Site Number :1560036, Shenyang
Investigational Site Number :3560001, New Delhi
Investigational Site Number :1560057, Changchun
Investigational Site Number :3560006, Chandigarh
Investigational Site Number :3560012, Mohali
Investigational Site Number :1560050, Shanghai
Investigational Site Number :1560049, Shanghai
Investigational Site Number :1560005, Shanghai
Investigational Site Number :1560011, Shanghai
Investigational Site Number :1560017, Shanghai
Investigational Site Number :1560006, Shanghai
Investigational Site Number :1560002, Shanghai
Investigational Site Number :1560051, Nanjing
Investigational Site Number :1560054, Nanjing
Investigational Site Number :1560037, Nanjing
Investigational Site Number :1560031, Suzhou
Investigational Site Number :1560023, Xuzhou
Investigational Site Number :1560055, Yangzhou
Investigational Site Number :1560020, Tianjin
Investigational Site Number :3560005, Jaipur
Investigational Site Number :3560015, Jaipur
Investigational Site Number :1560019, Hangzhou
Investigational Site Number :1560007, Hangzhou
Investigational Site Number :1560014, Hangzhou
Investigational Site Number :1560026, Hangzhou
Investigational Site Number :1560021, Wenzhou
Investigational Site Number :1560024, Nanchang
Investigational Site Number :1560035, Pingxiang
Investigational Site Number :1560046, Xiamen
Investigational Site Number :1560025, Chongqing
Investigational Site Number :1560010, Changsha
Investigational Site Number :3560009, Pune
Investigational Site Number :1560052, Wuhan
Investigational Site Number :1560028, Wuhan
Investigational Site Number :3560003, Nagpur
Investigational Site Number :3560016, Nagpur
Investigational Site Number :3560013, Hyderabad
Investigational Site Number :1560004, Guangzhou
Investigational Site Number :1560001, Guangzhou
Investigational Site Number :1560045, Guangzhou
Investigational Site Number :1560012, Shenzhen
Investigational Site Number :1560042, Shenzhen
Investigational Site Number :1560047, Zhanjiang
Investigational Site Number :1560032, Guiyang
Investigational Site Number :1560030, Chengdu
Investigational Site Number :3560007, Vellore
Investigational Site Number :3560002, Coimbatore
Investigational Site Number :3560011, Kozhikode
Investigational Site Number :3560010, Kolkata
Investigational Site Number :1560022, Lanzhou
Investigational Site Number :1560033, Ürümqi
Investigational Site Number :1560013, Baotou
Investigational Site Number :1560056, Beijing
Investigational Site Number :1560053, Chengdu
Investigational Site Number :1560043, Hangzhou
Investigational Site Number :1560038, Hefei
Investigational Site Number :1560040, Xi'an
Investigational Site Number :1560027, Xiangtan
Investigational Site Number :1560044, Hohhot
Investigational Site Number :1560008, Hohhot
Investigational Site Number :1560003, Shijiazhuang
Investigational Site Number :1560041, Shijiazhuang
Investigational Site Number :1560048, Taiyuan
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY